BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25980534)

  • 21. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery.
    Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH
    Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
    Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
    Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.
    Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z
    Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
    van Lummel M; van Blitterswijk WJ; Vink SR; Veldman RJ; van der Valk MA; Schipper D; Dicheva BM; Eggermont AM; ten Hagen TL; Verheij M; Koning GA
    FASEB J; 2011 Jan; 25(1):280-9. PubMed ID: 20876209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. pH-triggered intracellular release from actively targeting polymer micelles.
    Guo X; Shi C; Wang J; Di S; Zhou S
    Biomaterials; 2013 Jun; 34(18):4544-54. PubMed ID: 23510854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel delivery system of doxorubicin with high load and pH-responsive release from the nanoparticles of poly (α,β-aspartic acid) derivative.
    Wang X; Wu G; Lu C; Zhao W; Wang Y; Fan Y; Gao H; Ma J
    Eur J Pharm Sci; 2012 Aug; 47(1):256-64. PubMed ID: 22522116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Charge-conversional PEG-polypeptide polyionic complex nanoparticles from simple blending of a pair of oppositely charged block copolymers as an intelligent vehicle for efficient antitumor drug delivery.
    Lv S; Song W; Tang Z; Li M; Yu H; Hong H; Chen X
    Mol Pharm; 2014 May; 11(5):1562-74. PubMed ID: 24606535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction and evaluation of PAMAM-DOX conjugates with superior tumor recognition and intracellular acid-triggered drug release properties.
    Cheng L; Hu Q; Cheng L; Hu W; Xu M; Zhu Y; Zhang L; Chen D
    Colloids Surf B Biointerfaces; 2015 Dec; 136():37-45. PubMed ID: 26360738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
    Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
    J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyaluronate tethered, "smart" multiwalled carbon nanotubes for tumor-targeted delivery of doxorubicin.
    Datir SR; Das M; Singh RP; Jain S
    Bioconjug Chem; 2012 Nov; 23(11):2201-13. PubMed ID: 23039830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery.
    Han HS; Thambi T; Choi KY; Son S; Ko H; Lee MC; Jo DG; Chae YS; Kang YM; Lee JY; Park JH
    Biomacromolecules; 2015 Feb; 16(2):447-56. PubMed ID: 25565417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
    Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A folate modified pH sensitive targeted polymeric micelle alleviated systemic toxicity of doxorubicin (DOX) in multi-drug resistant tumor bearing mice.
    Li X; Yang X; Lin Z; Wang D; Mei D; He B; Wang X; Wang X; Zhang Q; Gao W
    Eur J Pharm Sci; 2015 Aug; 76():95-101. PubMed ID: 25917524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery.
    Prabaharan M; Grailer JJ; Pilla S; Steeber DA; Gong S
    Biomaterials; 2009 Oct; 30(30):6065-75. PubMed ID: 19674777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pH-sensitive hyaluronic acid prodrug modified with lactoferrin for glioma dual-targeted treatment.
    Yin Y; Fu C; Li M; Li X; Wang M; He L; Zhang LM; Peng Y
    Mater Sci Eng C Mater Biol Appl; 2016 Oct; 67():159-169. PubMed ID: 27287110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doxorubicin-polyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics.
    Chun C; Lee SM; Kim CW; Hong KY; Kim SY; Yang HK; Song SC
    Biomaterials; 2009 Sep; 30(27):4752-62. PubMed ID: 19520429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alendronate conjugate for targeted delivery to bone-forming prostate cancer.
    Damasco JA; Yu G; Kumar A; Perez J; Lirag RCM; Whitley EM; Lin SH; Melancon MP
    Talanta; 2023 May; 256():124308. PubMed ID: 36774896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyaluronic acid-decorated graphene oxide nanohybrids as nanocarriers for targeted and pH-responsive anticancer drug delivery.
    Song E; Han W; Li C; Cheng D; Li L; Liu L; Zhu G; Song Y; Tan W
    ACS Appl Mater Interfaces; 2014 Aug; 6(15):11882-90. PubMed ID: 25000539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.